Investors turn on biotechnology as largest ETF in sector suffers record withdrawals

But analysts divided over longer-term prospects: Some see end of bull market while others see pause

Apr 8, 2014 @ 1:19 pm

Investors pulled a record $372 million from the biggest biotechnology exchange-traded fund in its worst day of redemptions ever.

The withdrawals from the iShares Nasdaq Biotechnology ETF on April 4 were the most since its 2001 inception, with 7.5% of the fund's $4.98 billion in total assets leaving what is the biggest biotech-focused ETF, according to data compiled by Bloomberg. It follows a lengthy run-up in biotechnology industry stocks.

Now, “that momentum money is being sucked out,” said Geoffrey Porges, an analyst with Sanford C. Bernstein & Co.

Health-care ETFs have boomed this year, attracting more deposits than any other sector and adding $3.98 billion since Jan. 1. That increase has been spurred by a biotechnology sector that last year gained 74%, compared with a 30% increase in the S&P 500.

Recently, investors have begun to question whether biotechnology stocks are in a bubble and whether the companies developing complex and often expensive medicines are worth their high valuations. After gaining 11% in January and February, the Standard & Poor's 500 Biotechnology Index has fallen 11% since March 3.


“We consider the sector's run-up, which has been remarkable, to be getting into its very final innings,” Mr. Porges said. Stocks could be set for a significant move downward, especially if generalist investors decide to leave, he said.

Robyn Karnauskas, an analyst with Deutsche Bank AG, disagrees.

“The way I see it, I think we've turned the corner,” she said. “I don't see this as downside. When the fundamentals are strong and you have catalysts like earnings, I don't think we're headed for a bear period.”

The Nasdaq Biotechnology exchange-traded fund, also known as the IBB, is made up of the shares for 122 biotechnology and medical companies including its biggest holdings — Amgen Inc., Gilead Sciences Inc. and Celgene Corp. The SPDR S&P Biotech ETF also had its worst day since May 2010 on April 4 as investors pulled $80 million, or 6.6% of assets.


There are other signs investors are pessimistic. In the Nasdaq Biotechnology ETF, 15% of all the shares outstanding — $665 million worth — are short, meaning investors have bet they'll fall in value, according to data compiled by Bloomberg and Markit Group Ltd.

Other health-care focused ETFs with more diversified assets didn't see similar withdrawals. For example, the Health Care Select Sector SPDR Fund, which also has pharmaceuticals and health-care products and services stocks, gained $90 million on the biotech ETF's worst day.

Some of that may be profit-taking near the end of the quarter, said Paul Weisbruch, a vice president at Street One Financial. “It's a reflection of, probably, end-of-the-quarter selling of the winners if you will, because biotechs have done really well,” he said. His firm analyzes and trades ETFs.

Investors aren't just moving out of biotech funds, they're also exiting more volatile sectors that haven't fared well recently, he said.

Industries with high volatility are what “you see selling off — small caps, social media,” Mr. Weisbruch said. “As fast as it went up, it's coming down.”

(Bloomberg News)


What do you think?

View comments

Recommended for you

Featured video


Are investors getting complacent?

Tom Florence, CEO of 361 Capital, discusses growing investor complacency and why he thinks overconfidence might be creeping into adviser and investor decision making.

Latest news & opinion

Nontraded BDC sales in worst year since 2010

The illiquid product's three-year decline is partially due to new regulations and poor performance.

Tax reform debate sparks fresh interest in donor-advised funds

Schwab reports new accounts up 50% from last year, assets up 33%.

Nontraded REITs to post worst sales since 2002

The industry is on track to raise just $4.4 billion, well off the $19.6 billion it raised just four years ago, as new regulations hinder sales.

Broker protocol for recruiting a boon for clients

New research finds advisers whose firms have joined the agreement take better care of customers.

Meet our 2017 Women to Watch

Introducing 20 female financial advisers and industry executives who are distinguished leaders, advancing the business of providing advice through their creativity and hard work.


Subscribe and Save 60%

Premium Access
Print + Digital

Learn more
Subscribe to Print